This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
by Zacks Equity Research
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of -100% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
by Zacks Equity Research
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
by Zacks Equity Research
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
STE Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
by Zacks Equity Research
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA
by Zacks Equity Research
Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
by Zacks Equity Research
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?
by Zacks Equity Research
Strength in kidney care services and expansion into international markets raise optimism for DVA stock.
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
by Zacks Equity Research
Dexcom announces the first Generative AI platform in glucose biosensing.
Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
NVRO's continued technological innovations and business diversification plans raise optimism about the stock.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors owing to its strong product portfolio.